# Breast Neoplasms FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/breast-neoplasms

> 14 upcoming FDA catalysts in breast Neoplasms: Piqray (alpelisib, NVS) on Jan to Apr 2027 (topline data readout); Piqray (alpelisib, NVS) on January 2027 (primary completion); KEYTRUDA® (pembrolizumab, MRK) on Jul to Oct 2027 (topline data readout); KEYTRUDA® (pembrolizumab, MRK) on July 2027 (primary completion); and 10 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 24, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | completed | "NCT04895358 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-24 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895358)) |
| Jan to Apr 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Neoplasms | scheduled | "NCT04544189 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04544189)) |
| January 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Neoplasms | scheduled | "NCT04544189 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04544189)) |
| Jul to Oct 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | scheduled | "NCT06312176 (A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-11 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312176)) |
| July 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | scheduled | "NCT06312176 (A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-11 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312176)) |
| October 2027 | [Inluriyo™ (imlunestrant) primary completion](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT05514054 (A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05514054)) |
| Oct 2027 to Jan 2028 | [Inluriyo™ (imlunestrant) topline data readout](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT05514054 (A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05514054)) |
| December 2027 | [VERZENIO (abemaciclib) primary completion](https://sec-api.dev/pdufa/abemaciclib) | LLY | Breast Neoplasms | scheduled | "NCT07935317 (A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07935317)) |
| Dec 2027 to Mar 2028 | [VERZENIO (abemaciclib) topline data readout](https://sec-api.dev/pdufa/abemaciclib) | LLY | Breast Neoplasms | scheduled | "NCT07935317 (A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07935317)) |
| Mar to Jun 2028 | [Iza-bren topline data readout](https://sec-api.dev/pdufa/iza-bren) | BMY | Breast Neoplasms | scheduled | "NCT06926868 (A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06926868)) |
| March 2028 | [Iza-bren primary completion](https://sec-api.dev/pdufa/iza-bren) | BMY | Breast Neoplasms | scheduled | "NCT06926868 (A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06926868)) |
| January 2029 | [Inluriyo™ (imlunestrant) primary completion](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT07287098 (A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287098)) |
| Jan to Apr 2029 | [Inluriyo™ (imlunestrant) topline data readout](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT07287098 (A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287098)) |
| December 2029 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Breast Neoplasms | scheduled | "NCT07173751 (ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07173751)) |
| Dec 2029 to Mar 2030 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Breast Neoplasms | scheduled | "NCT07173751 (ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07173751)) |

## Drugs

- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Inluriyo™ (imlunestrant)](https://sec-api.dev/pdufa/imlunestrant) (LLY)
- [VERZENIO (abemaciclib)](https://sec-api.dev/pdufa/abemaciclib) (LLY)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/breast-neoplasms.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Breast Neoplasms FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/breast-neoplasms

```bibtex
@misc{secapidev_indications_breast_neoplasms_20261116,
  title        = {Breast Neoplasms FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/breast-neoplasms}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_breast_neoplasms_20261116","title":"Breast Neoplasms FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/breast-neoplasms","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
